Arizona Senate approved a budget bill that included provisions to fund medical research on the potential of psilocybin mushroom for treating a wide range of conditions.
Instead of enacting the reform via a standalone bill on psychedelics that was introduced earlier in this session, top legislators and the governor decided to incorporate the proposal within appropriations measures.
On Wednesday, the Senate passed a bill appropriating $5 million for psilocybin-related research. The Senate also passed a health-focused budget measure, which details the requirements for the clinical trial that the dollars will fund. The House gave initial approval to versions that are companions of legislation. Final passage is expected shortly.
The standalone psilocybin legislation that was unanimously approved by in February of the House Military Affairs & Public Safety Committee would have provided $30 million over three years for the research.
According to the budget legislation approved, the Department of Health Services of the State of California (DHS) will distribute $5 million in fiscal year 2023-2024 towards “whole-mushroom psilocybin Phase One, Phase Two, and Stage Three clinical trials which are capable of approval” by the Food and Drug Administration of the United States (FDA), for treatment of any of the thirteen listed conditions.
Among these conditions are post-traumatic disorder (PTSD), anxiety, depression, COVID long symptoms, and substance abuse disorder.
Grant money will be given to researchers who have used psilocybin in their trials with the approval of the federal Drug Enforcement Administration. These researchers include veterans, first responders and health care workers, as well as people from underserved areas.
The bill would not legalize psilocybin, as lawmakers in other states aim to do. However, people who receive grant money and work on clinical trials will be explicitly protected under the bill.
The DHS would establish a “Psilocybin Advisory Council,” which is tasked with creating eligibility criteria for grant applicants, overseeing application submissions and making “recommendations on psychedelic assisted therapy based upon current federal and state policy.”
According to the bill, the council must include the DHS Director, a doctor with a federal license for studying psychedelics and a veteran of the military, as well as a law-enforcement official, a professor, or researcher, from an Arizona university.
Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.
Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.
—
This session, a number of lawmakers from across the U.S. are pursuing reforms relating to psychedelics. They have focused on measures focusing on research and therapeutic uses.
The governor of Washington State, for example, has signed a law on Tuesday that promotes research in psilocybin. It also creates a pilot program allowing therapeutic access to psychedelics to treat mental illness.
Last week, Vermont legislators held a hearing in which members discussed legislation that would legalize psilocybin. They also took the first steps towards providing regulated access.
A California bill to legalize possession of certain psychoactive substances and facilitate their use is headed to the Senate Floor under an accelerated process , which allows it to bypass further committee consideration.
The Minnesota House passed a health bill omnibus that includes provisions for the creation of a psychedelics Task Force to prepare Minnesota for possible legalization.
A bipartisan group and a Republican North Carolina legislator filed a bill last month to create a grant program of $5 million to support research on the potential therapeutic benefits of psilocybin, and to create a Breakthrough Therapies Research Advisory Board.
Last month, a Nevada Senate Committee approved a revised version of a bill that would establish a new group to study psychedelics as well as develop a plan for regulated access to therapeutic purposes.
Last month, the Hawaii Senate passed a bill to establish an advisory council that would examine possible regulations to allow access to federal “breakthrough therapy” such as psilocybin or MDMA.
Oregon regulators approved a license for the first psilocybin services center in the country. People will be able use the psychedelic under a controlled and facilitated setting.
Nora Volkow, director of the National Institute on Drug Abuse, told senators in a statement last week that new evidence is emerging that psychoedelics have “significant potential” to be used as therapeutic treatments for some mental health conditions. This topic, she said, is “of great interest” to researchers.
Based on statistical modelling of policy trends, an analysis published last year in the American Medical Association journal concluded that most states will legalize psychedelics before 2037.
A March national poll found that the majority of U.S. citizens support access to psychedelic therapy , and are in favor of federal decriminalization substances such as psilocybin or MDMA.
The article Arizona Lawmakers approve Psilocybin research grants as part of budget first appeared on Marijuana Moment.
